ea0081oc4.1 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022
Klose Marianne
, Huynh Kim
, Tfelt Jacob
, Krogsgaard Kim
, Drejer Jorgen
, Byberg Sarah
, Madsbad Sten
, Magkos Faidon
, Aharaz Abdellatif
, Edsberg Berit
, Astrup Arne
, Feldt-Rasmussen Ulla
Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...